Differential prefrontal gray matter correlates of treatment response to fluoxetine or cognitive-behavioral therapy in obsessive-compulsive disorder

European Neuropsychopharmacology

Volumn 23, Issue 7, 2013, Pages 569-580

  Hoexter, Marcelo Q ^a,b,c   Dougherty, Darin D ^c   Shavitt, Roseli G ^a   D'Alcante, Carina C ^a   Duran, Fabio L S ^a   Lopes, Antonio C ^a   Diniz, Juliana B ^a   Batistuzzo, Marcelo C ^a   Evans, Karleyton C ^c   Bressan, Rodrigo A ^b   Busatto, Geraldo F ^a   Miguel, Euripedes C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cognitive behavioral therapy; Gray matter; Neuroimaging; OCD; Serotonergic reuptake inhibitor

Indexed keywords

FLUOXETINE;

ADULT; ARTICLE; ATTENTION; BRAIN REGION; BRAIN SIZE; COGNITIVE THERAPY; DRUG DOSE INCREASE; FEMALE; GRAY MATTER; HUMAN; INTELLIGENCE QUOTIENT; MAJOR CLINICAL STUDY; MALE; MEDIAL PREFRONTAL CORTEX; MOTOR COORDINATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSESSIVE COMPULSIVE DISORDER; ORBITAL CORTEX; PREFRONTAL CORTEX; PREMEDICATION; PRIORITY JOURNAL; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE; VOXEL BASED MORPHOMETRY; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ADULT; ATROPHY; COGNITIVE THERAPY; FEMALE; FLUOXETINE; HUMANS; MALE; NERVE FIBERS, UNMYELINATED; NEUROIMAGING; NEUROPSYCHOLOGICAL TESTS; OBSESSIVE-COMPULSIVE DISORDER; PREDICTIVE VALUE OF TESTS; PREFRONTAL CORTEX; PSYCHOTHERAPY, GROUP; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84878856125     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.06.014     Document Type: Article

References (57)

1. Ashburner J., Friston K.J. Unified segmentation. Neuroimage 2005, 26:839-851.
2. Baxter L.R., Schwartz J.M., Bergman K.S., Szuba M.P., Guze B.H., Mazziotta J.C., Alazraki A., Selin C.E., Ferng H.K., Munford P., et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch. Gen. Psychiatry 1992, 49:681-689.
3. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry 1961, 4:561-571.
4. Beck A.T., Epstein N., Brown G., Steer R.A. An inventory for measuring clinical anxiety: psychometric properties. J. Consult. Clin. Psychol. 1988, 56:893-897.
5. Belotto-Silva C., Diniz J.B., Malavazzi D.M., Valério C., Fossaluza V., Borcato S., Seixas A.A., Morelli D., Migue E.C., Shavitt R.G. Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trial. J. Anxiety Disord. 2012, 26:25-31.
6. Benazon N.R., Moore G.J., Rosenberg D.R. Neurochemical analyses in pediatric obsessive-compulsive disorder in patients treated with cognitive-behavioral therapy. J. Am. Acad. Child Adolesc. Psychiatry 2003, 42:1279-1285.
7. Brett M., Johnsrude I.S., Owen A.M. The problem of functional localization in the human brain. Nat. Rev. Neurosci. 2002, 3:243-249.
8. Brody A.L., Saxena S., Schwartz J.M., Stoessel P.W., Maidment K., Phelps M.E., Baxter L.R. FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. Psychiatry Res. 1998, 84:1-6.
9. Cardoner N., Soriano-Mas C., Pujol J., Alonso P., Harrison B.J., Deus J., Hernández-Ribas R., Menchón J.M., Vallejo J. Brain structural correlates of depressive comorbidity in obsessive-compulsive disorder. Neuroimage 2007, 38:413-421.
10. Chamberlain S.R., Menzies L., Hampshire A., Suckling J., Fineberg N.A., del Campo N., Aitken M., Craig K., Owen A.M., Bullmore E.T., Robbins T.W., Sahakian B.J. Orbitofrontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives. Science 2008, 321:421-422.
11. Cuadra M.B., Cammoun L., Butz T., Cuisenaire O., Thiran J.P. Comparison and validation of tissue modelization and statistical classification methods in T1-weighted MR brain images. IEEE Trans. Med. Imaging 2005, 24:1548-1565.
12. Czeh B., Muller-Keuker J.I., Rygula R., Abumaria N., Hiemke C., Domenici E., Fuchs E. Chronic social stress inhibits cell proliferation in the adult medial prefrontal cortex: hemispheric asymmetry and reversal by fluoxetine treatment. Neuropsychopharmacology 2007, 32:1490-1503.
13. Derryberry D., Tucker D.M. Neural mechanisms of emotion. J. Consult. Clin. Psychol. 1992, 60:329-338.
14. Diniz J., Shavitt R., Pereira C., Hounie A., Pimentel I., Koran L., Dainesi S., Miguel E. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial. J. Psychopharmacol. 2009, 24:297-307.
15. Dougherty D.D., Weiss A.P., Cosgrove G.R., Alpert N.M., Cassem E.H., Nierenberg A.A., Price B.H., Mayberg H.S., Fischman A.J., Rauch S.L. Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for treatment of major depression. J. Neurosurg. 2003, 99:1010-1017.
16. el Mansari M., Bouchard C., Blier P. Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Relevance to treatment of obsessive-compulsive disorder. Neuropsychopharmacology 1995, 13:117-127.
17. Evans K.C., Dougherty D.D., Pollack M.H., Rauch S.L. Using neuroimaging to predict treatment response in mood and anxiety disorders. Ann. Clin. Psychiatry 2006, 18:33-42.
18. Evans K.C., Simon N.M., Dougherty D.D., Hoge E.A., Worthington J.J., Chow C., Kaufman R.E., Gold A.L., Fischman A.J., Pollack M.H., Rauch S.L. A PET study of tiagabine treatment implicates ventral medial prefrontal cortex in generalized social anxiety disorder. Neuropsychopharmacology 2009, 34:390-398.
19. First M., Spitzer R., Gibbon M., Williams J. Structured clinical interview for DSM-IV axis I disorders: clinical version (SCID CV) 1997, American Psychiatric Press, Washington, DC.
20. Fossaluza V., Diniz J.B., Pereira Bde B., Miguel E.C., Pereira C.A. Sequential allocation to balance prognostic factors in a psychiatric clinical trial. Clinics (Sao Paulo) 2009, 64:511-518.
21. Friston K., Holmes A., Worsley K., Poline J., Frith C., Frackowiak R. Statistic parametric maps in functional imaging: a general linear approach. Hum. Brain Mapp. 1994, 2:189-210.
22. Garner B., Berger G.E., Nicolo J.P., Mackinnon A., Wood S.J., Pariante C.M., Dazzan P., Proffitt T.M., Markulev C., Kerr M., McConchie M., Phillips L.J., Pantelis C., McGorry P.D. Pituitary volume and early treatment response in drug-naïve first-episode psychosis patients. Schizophr. Res. 2009, 113:65-71.
23. Gilbert A.R., Moore G.J., Keshavan M.S., Paulson L.A., Narula V., Mac Master F.P., Stewart C.M., Rosenberg D.R. Decrease in thalamic volumes of pediatric patients with obsessive-compulsive disorder who are taking paroxetine. Arch. Gen. Psychiatry 2000, 57:449-456.
24. Goldapple K., Segal Z., Garson C., Lau M., Bieling P., Kennedy S., Mayberg H. Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch. Gen. Psychiatry 2004, 61:34-41.
25. Good C.D., Johnsrude I.S., Ashburner J., Henson R.N., Friston K.J., Frackowiak R.S. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 2001, 14:21-36.
26. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., Heninger G.R., Charney D.S. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch. Gen. Psychiatry 1989, 46:1006-1011.
27. Greenberg B.D., Malone D.A., Friehs G.M., Rezai A.R., Kubu C.S., Malloy P.F., Salloway S.P., Okun M.S., Goodman W.K., Rasmussen S.A. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology 2006, 31:2384-2393.
28. Greenberg B.D., Rauch S.L., Haber S.N. Invasive circuitry-based neurotherapeutics: stereotactic ablation and deep brain stimulation for OCD. Neuropsychopharmacology 2010, 35:317-336.
29. Hoexter M.Q., Shavitt R.G., D'Alcante C.C., Cecconi J.P., Diniz J.B., Belotto-Silva C., Hounie A.G., Borcato S., Moraes I., Joaquim M.A., Cappi C., Sampaio A.S., Mathis M.A., Batistuzzo M.C., Lopes A.C., Rosa A.C., Muniz R.K., Marques A.H., Santos L.C., Taub A., Duran F.L., Dougherty D.D., Busatto G.F., Bressan R.A., Miguel E.C. The drug-naive OCD patients imaging genetics, cognitive and treatment response study: methods and sample description. Rev. Bras. Psiquiatr. 2009, 31:349-353.
30. Hoexter M.Q., de Souza Duran F.L., D'Alcante C.C., Dougherty D.D., Shavitt R.G., Lopes A.C., Diniz J.B., Deckersbach T., Batistuzzo M.C., Bressan R.A., Miguel E.C., Busatto G.F. Gray matter volumes in obsessive-compulsive disorder before and after fluoxetine or cognitive-behavior therapy: a randomized clinical trial. Neuropsychopharmacology 2012, 37:734-745.
31. Jones D.K., Symms M.R., Cercignani M., Howard R.J. The effect of filter size on VBM analyses of DT-MRI data. Neuroimage 2005, 26:546-554.
32. Koran L.M., Hanna G.L., Hollander E., Nestadt G., Simpson H.B. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am. J. Psychiatry 2007, 164:5-53.
33. MacQueen G.M. Magnetic resonance imaging and prediction of outcome in patients with major depressive disorder. J. Psychiatry Neurosci. 2009, 34:343-349.
34. Mancebo M.C., Eisen J.L., Pinto A., Greenberg B.D., Dyck I.R., Rasmussen S.A. The brown longitudinal obsessive compulsive study: treatments received and patient impressions of improvement. J. Clin. Psychiatry 2006, 67:1713-1720.
35. Martin S.D., Martin E., Rai S.S., Richardson M.A., Royall R. Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings. Arch. Gen. Psychiatry 2001, 58:641-648.
36. Mayberg H.S., Brannan S.K., Mahurin R.K., Jerabek P.A., Brickman J.S., Tekell J.L., Silva J.A., McGinnis S., Glass T.G., Martin C.C., Fox P.T. Cingulate function in depression: a potential predictor of treatment response. Neuroreport 1997, 8:1057-1061.
37. McCormick L.M., Ziebell S., Nopoulos P., Cassell M., Andreasen N.C., Brumm M. Anterior cingulate cortex: an MRI-based parcellation method. NeuroImage 2006, 32:1167-1175.
38. Menzies L., Chamberlain S.R., Laird A.R., Thelen S.M., Sahakian B.J., Bullmore E.T. Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited. Neurosci. Biobehav. Rev. 2008, 32:525-549.
39. Miguel E.C., Ferrao Y.A., Rosario M.C., Mathis M.A., Torres A.R., Fontenelle L.F., Hounie A.G., Shavitt R.G., Cordioli A.V., Gonzalez C.H., Petribu K., Diniz J.B., Malavazzi D.M., Torresan R.C., Raffin A.L., Meyer E., Braga D.T., Borcato S., Valerio C., Gropo L.N., Prado Hda S., Perin E.A., Santos S.I., Copque H., Borges M.C., Lopes A.P., Silva E.D. The Brazilian research consortium on obsessive-compulsive spectrum disorders: recruitment, assessment instruments, methods for the development of multicenter collaborative studies and preliminary results. Rev. Bras. Psiquiatr. 2008, 30:185-196.
40. Milad M.R., Quinn B.T., Pitman R.K., Orr S.P., Fischl B., Rauch S.L. Thickness of ventromedial prefrontal cortex in humans is correlated with extinction memory. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:10706-10711.
41. Milad M.R., Wright C.I., Orr S.P., Pitman R.K., Quirk G.J., Rauch S.L. Recall of fear extinction in humans activates the ventromedial prefrontal cortex and hippocampus in concert. Biol. Psychiatry 2007, 62:446-454.
42. Phelps E.A., Delgado M.R., Nearing K.I., LeDoux J.E. Extinction learning in humans: role of the amygdala and vmPFC. Neuron 2004, 43:897-905.
43. Quirk G.J., Garcia R., González-Lima F. Prefrontal mechanisms in extinction of conditioned fear. Biol. Psychiatry 2006, 60:337-343.
44. Rauch S.L., Jenike M.A., Alpert N.M., Baer L., Breiter H.C., Savage C.R., Fischman A.J. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch. Gen. Psychiatry 1994, 51:62-70.
45. Reitan R., Wolfson D. The Halstead-Reitan neuropsychological test battery: theory and clinical interpretation 1985, Neuropsychology Press, Tucson, AZ.
46. Rosario-Campos M.C., Miguel E.C., Quatrano S., Chacon P., Ferrao Y., Findley D., Katsovich L., Scahill L., King R.A., Woody S.R., Tolin D., Hollander E., Kano Y., Leckman J.F. The Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS): an instrument for assessing obsessive-compulsive symptom dimensions. Mol. Psychiatry 2006, 11:495-504.
47. Rosenberg D.R., Benazon N.R., Gilbert A., Sullivan A., Moore G.J. Thalamic volume in pediatric obsessive-compulsive disorder patients before and after cognitive behavioral therapy. Biol. Psychiatry 2000, 48:294-300.
48. Saxena S., Brody A.L., Maidment K.M., Dunkin J.J., Colgan M., Alborzian S., Phelps M.E., Baxter L.R. Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 1999, 21:683-693.
49. Saxena S., Rauch S.L. Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatr. Clin. North Am. 2000, 23:563-586.
50. Saxena S., Brody A.L., Ho M.L., Zohrabi N., Maidment K.M., Baxter L.R. Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. Am. J. Psychiatry 2003, 160:522-532.
51. Schwartz J.M., Stoessel P.W., Baxter L.R., Martin K.M., Phelps M.E. Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. Arch. Gen. Psychiatry 1996, 53:109-113.
52. Soumier A., Banasr M., Goff L.K., Daszuta A. Region- and phase-dependent effects of 5-HT(1A) and 5-HT(2C) receptor activation on adult neurogenesis. Eur. Neuropsychopharmacol. 2009, 20:336-345.
53. Talairach J., Tournoux P., Fischer M. Co-Planar Stereotaxic Atlas of the Human Brain 1988, Thieme Medical Publishers, New York.
54. Tucker D.M., Luu P., Pribram K.H. Social and emotional self-regulation. Ann. N.Y. Acad. Sci. 1995, 769:213-239.
55. Valente A.A., Miguel E.C., Castro C.C., Amaro E., Duran F.L., Buchpiguel C.A., Chitnis X., McGuire P.K., Busatto G.F. Regional gray matter abnormalities in obsessive-compulsive disorder: a voxel-based morphometry study. Biol. Psychiatry 2005, 58:479-487.
56. Van Laere K., Nuttin B., Gabriels L., Dupont P., Rasmussen S., Greenberg B.D., Cosyns P. Metabolic imaging of anterior capsular stimulation in refractory obsessive-compulsive disorder: a key role for the subgenual anterior cingulate and ventral striatum. J. Nucl. Med. 2006, 47:740-747.
57. Wechsler D. Wechsler abbreviated scale of IQ 1999, Psychological Corporation, Harcourt Brace and Company, San Antonio, TX.